The Abu Dhabi Public Health Centre (ADPHC) has entered into a Memorandum of Understanding (MoU) with Novartis Middle East FZE to enhance public health awareness and improve disease prevention, particularly focusing on cardiovascular diseases, diabetes, and chronic kidney disease in the Abu Dhabi Emirate. This agreement aims to raise awareness and advance disease management practices.

The MoU was signed by H.E. Rashed Obaid Alsuwaidi, Director General of ADPHC, and Mohamed Ezz Eldin, Head of GCC at Novartis, on May 13, during the 25th IUHPE World Conference on Health Promotion, taking place from May 13 to May 16, 2025, at the Abu Dhabi National Exhibition Centre (ADNEC).

H.E. Rashed Obaid Alsuwaidi stated that this MoU marks a crucial step towards strengthening public health systems and decreasing the impact of non-communicable diseases in Abu Dhabi. He emphasized the goal of delivering long-term, sustainable health outcomes for the population through strategic collaborations.

Mohamed Ezz Eldin expressed pride in partnering with ADPHC, stating that the collaboration aligns with Novartis’ commitment to enhancing patient care. He highlighted the belief that together they could significantly impact patients’ lives through increased awareness, early detection, and proactive disease management. The partnership aims to merge public health initiatives with private sector innovation to foster healthier lifestyles and improve community well-being.

Under the two-year agreement, ADPHC and Novartis will work together to develop and implement awareness campaigns across both digital and traditional channels. These campaigns will focus on educating the public about risk factors, early symptoms, and the importance of regular screenings for non-communicable diseases.

The collaboration is structured around three strategic pillars:

1. **Disease Awareness**: Both entities will co-develop impactful campaigns to raise awareness and educate communities about non-communicable diseases such as cardiovascular conditions, diabetes, and chronic kidney disease. These initiatives will promote proactive health behaviors like routine testing.

2. **Disease Prevention**: The partnership will design and implement initiatives aimed at the primary prevention of cardiovascular diseases, diabetes, and chronic kidney disease in adults. This includes targeted screening efforts to identify at-risk individuals early.

3. **Best Practice Sharing in Disease Management**: The collaboration will focus on identifying, sharing, and implementing best practices across the patient journey. This involves early screening protocols, preventive strategies, and disease management models that draw on global expertise to enhance patient outcomes and improve healthcare system performance.

The MoU also establishes a dedicated taskforce, with each organization appointing a lead to coordinate efforts. This taskforce will meet regularly to ensure alignment on project plans, assess feasibility, define deliverables, and evaluate outcomes using jointly agreed key performance indicators (KPIs). These KPIs will be reviewed biannually to maintain alignment with strategic goals and adapt to emerging public health needs.

The Abu Dhabi Public Health Centre was established under law No. (14) of 2019, issued by the late His Highness Sheikh Khalifa bin Zayed Al Nahyan, with the aim of preserving the health of the Emirate’s population and ensuring worker safety through the promotion of public and preventive health concepts.